Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Defensin (HNP-1) peptide icon, one bubble per amino acidDefensin (HNP-1)30 residuesACYCRIPACIAGERRYGTCIYQGRLWAFCCEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Defensin (HNP-1)

ImmuneResearch
~3-4 hours half-life (estimated)·Injection·8w on / 4w off

Also known as: HNP-1, HNP1, Human Neutrophil Defensin 1

Over 1,000 PubMed papers cover defensin biology, yet zero human clinical trials have been completed. Human Neutrophil Peptide-1 (HNP-1) is a 30-amino-acid alpha-defensin that makes up 5 to 7 percent of total neutrophil protein. It kills bacteria, fungi, and enveloped viruses by punching holes in their membranes. The catch: no one has formally tested exogenous HNP-1 in humans as a therapeutic agent. Manufacturing is the bottleneck. Three intramolecular disulfide bonds must form in a precise pattern, making production expensive and quality verification difficult. Immunology researchers studying innate defense mechanisms use it most; as a lab reagent, it runs roughly $250 per 0.1 mg.

What Is Defensin (HNP-1)?

Human Neutrophil Peptide-1 (HNP-1) is an alpha-defensin stored in neutrophil azurophilic granules and one of the first-line antimicrobial peptides your immune system deploys. Over a thousand published papers exist, but not a single human clinical trial. When neutrophils detect infection, they release HNP-1 in bulk. The peptide carries a net +3 charge at physiological pH. That cationic charge pulls it toward the negatively charged membranes of bacteria, fungi, and enveloped viruses. Once bound, HNP-1 oligomerizes, inserts into the lipid bilayer, and forms pores that collapse transmembrane gradients. The result is osmotic lysis.

The peptide also does something more interesting. It recruits immune cells. HNP-1 binds CCR6 on immature dendritic cells and memory T cells, functioning as a chemokine. It promotes dendritic cell maturation, upregulates MHC class II expression, and activates macrophages through TLR4-dependent NF-kB signaling. This means HNP-1 connects innate and adaptive immunity; it kills pathogens directly and then calls in reinforcements.

Anti-HIV activity has been confirmed in cell-free assays (Chang et al., 2005)[1]. But a 2015 study in epithelial cell models [2] found HNP-1 disrupts epithelial tight junctions, increasing HIV traversal of mucosal barriers. That paradox alone makes clinical development complicated.

Research-grade HNP-1 costs $250 to $400 per 0.1 mg and is sold only as a lab reagent. No compounded versions exist. The gray market has essentially zero availability. Anyone exploring this compound is working in a serious research context.

How Defensin (HNP-1) Works

HNP-1 works through two distinct pathways: direct membrane destruction and receptor-mediated immune signaling.

The antimicrobial mechanism is straightforward. HNP-1 carries a net +3 cationic charge. Microbial membranes are rich in anionic phospholipids; mammalian membranes are mostly zwitterionic. That charge difference creates selectivity. HNP-1 binds the microbial surface, oligomerizes, and inserts into the bilayer to form multimeric pores. Transmembrane gradients collapse. The cell lyses.

Gram-negative bacteria add a step. HNP-1 first displaces the Mg2+ and Ca2+ cations stabilizing LPS in the outer membrane. Only after breaching that barrier does it reach the inner membrane for pore formation. Against enveloped viruses like HIV-1, HNP-1 disrupts glycoprotein-mediated fusion and damages the viral lipid envelope directly [1].

The immunomodulatory pathway runs through CCR6 receptors on immature dendritic cells and memory T cells. HNP-1 is a chemoattractant, pulling these cells toward infection sites. It then promotes dendritic cell maturation by upregulating CD80, CD86, CD83, and MHC class II (Yang et al., 1999)[3]. Macrophage activation occurs via TLR4-dependent signaling, increasing phagocytic capacity and triggering NF-kB-driven release of TNF-alpha, IL-1beta, and IL-6. HNP-1 also activates complement by binding C1q and initiating the classical pathway.

Defensin (HNP-1) Benefits

  • Defensin HNP-1 benefits center on antimicrobial defense and innate immune activation.
  • Kills bacteria, fungi, and enveloped viruses through direct membrane pore formation. In vitro MIC values range from 1 to 10 mcg/mL across tested pathogen panels (Ganz, 2003)[4].
  • Recruits dendritic cells, monocytes, and naive T cells via CCR6 binding. This chemotactic function connects innate and adaptive immunity, a property confirmed in Yang et al.'s 1999 work [3].
  • Activates macrophage phagocytosis through TLR4/NF-kB signaling, increasing pathogen clearance capacity in animal models.
  • Boosts complement activation by binding C1q and triggering the classical pathway, adding another layer of immune defense beyond direct killing.
  • Selective cytotoxicity against certain cancer cell lines has been observed in vitro. Colorectal and bladder cancer studies have identified raised HNP-1 serum levels as potential biomarkers, though whether this is protective or simply reflects neutrophil activation remains unresolved.
  • HNP-1 makes up 5 to 7 percent of total neutrophil protein, making it one of the most abundant antimicrobial peptides in the human body. That biological prevalence suggests it plays a load-bearing role in first-line pathogen defense.

Defensin (HNP-1): Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 13 key studies·Research only

No human clinical trials exist.

Dosing studied: No established human dosing. Extrapolated from in vitro antimicrobial concentrations (MIC ~1–10 µg/mL) and animal studies; research tiers: 50 mcg SC 3×/week (conservative) to 200 mcg SC daily (aggressive). Animal sepsis studies used 0.5–10 mg/kg i.p.: 175–3,500× higher than research tiers.
Read the evidence (key study, limitations)

~1,000 PubMed publications cover defensin biology, but all human-relevant data is observational (endogenous levels) or extrapolated from in vitro MIC values and rodent models. Broad-spectrum antimicrobial and immunomodulatory activity well-established in basic science; exogenous therapeutic use unvalidated in humans.

Key Study

PMC11858525 (2025): structure-to-application review; PMID 12949495 (Ganz 2003): foundational antimicrobial peptide review; PMC11981803 (2025): HNP-1 activates SaeRS virulence system in S. aureus

Limitations

Zero Phase I/II/III clinical data. Manufacturing barrier: three intramolecular disulfide bonds require expensive synthetic chemistry. No formal PK study in any species for SC route. Critical HIV paradox: HNP-1 both inhibits cell-free HIV (PMID 15719067) and increases HIV mucosal traversal (PMID 26379091). High-dose sepsis worsening (PMC9355784) complicates use in any infection context.

Community Experience
Weak
3.5/5
Based on <5 anecdotal mentions

No organized self-experimentation community found.

Community dosing: No community dosing data available.
Read the reports (common issues 1)

Fewer than 20 Reddit threads, all academic/discussion rather than protocol-sharing. No anecdotal dosing reports, stacking logs, or outcome data. This compound exists solely in research contexts.

What users report (0)
    Common issues (1)
    • No community experience to report: research-only compound with no accessible consumer market
    Science-Only Evidence

    Research exists (1,000+ papers on defensin biology) but no community self-experimentation exists. All dosing tiers are researcher-extrapolated estimates from in vitro MIC data, not real-world validated.

    Defensin (HNP-1) Dosage Guide

    SpeculativeResearch use only; no established human dosing protocol
    LevelDose / InjectionFrequency
    Beginner50 mcg
    3x/weekTrack
    Moderate100 mcg
    DailyTrack
    Aggressive200 mcg
    DailyTrack
    Note:

    HNP-1 is not part of the standard research-peptide market. Research-grade material, sold only as a lab reagent, runs roughly $250 to $400 per 0.1 mg. That price is telling you something about manufacturing difficulty.

    Reconstitution math for a 1 mg vial: add 2 mL bacteriostatic water to get 500 mcg/mL. A 50 mcg beginner dose is 0.10 mL (10 units on a U-100 insulin syringe). A 100 mcg moderate dose is 0.20 mL (20 units). A 200 mcg aggressive dose is 0.40 mL (40 units).

    Swirl gently when reconstituting. Defensins aggregate at air-water interfaces; shaking or vortexing will ruin your vial. If you see cloudiness after reconstituting, the product may be aggregated and should be discarded.

    A useful Certificate of Analysis includes disulfide bond confirmation by mass spectrometry or NMR. Standard HPLC purity testing does not confirm the three disulfide bonds formed correctly. Misfolded HNP-1 is inactive or potentially cytotoxic.

    Get baseline bloodwork before starting: CBC with differential, CRP, ESR, and liver function panel.

    Cycling Protocol

    On Period
    8 weeks
    Off Period
    4 weeks

    No established human cycling protocols exist. The 8-on/4-off recommendation is conservative and based on general immune peptide cycling principles. Monitor inflammatory markers (CRP, ESR) during use. Discontinue if signs of excessive inflammation develop.

    Calculate your Defensin (HNP-1) dose
    Free dosage calculator with syringe visualization

    Or use the universal Peptide Calculator for any peptide.

    Defensin (HNP-1) Protocols by Goal

    beginnerCommunity8 weeks on, 4 weeks off
    Tolerance assessment
    Wk 1-2
    50 mcg · 3×/week · subcutaneous
    Moderate escalation
    Wk 3-8
    100 mcg · Daily · subcutaneous

    Expected: Theoretical: enhanced innate immune activation (macrophage, DC, NK cell priming). No validated human outcome data exists. Observable markers: CBC with differential, inflammatory cytokines (TNF-α, IL-1β) if lab monitoring enabled.

    Monitor: CBC with differential at baseline and week 4/8. CRP and ESR at baseline and week 4. Liver function panel recommended given PMC9355784 liver junction disruption finding at high doses.

    How to Inject Defensin (HNP-1)

    1. 1
      Pull 2 mL of bacteriostatic water into a syringe

      Inject slowly against the inner wall of the vial containing 1 mg lyophilized HNP-1. This yields a concentration of 500 mcg/mL.

    2. 2
      Swirl the vial gently until the powder dissolves completely

      Do not shake, vortex, or invert vigorously. Defensins aggregate at air-water interfaces. A clear solution confirms proper reconstitution.

    3. 3
      Draw your dose using a U-100 insulin syringe

      Beginner: 10 units (50 mcg). Moderate: 20 units (100 mcg). Aggressive: 40 units (200 mcg).

    4. 4
      Choose an injection site on the abdomen

      Rotate sites with each injection to minimize local tissue irritation from the cationic charge.

    5. 5
      Step 5

      Use a 29 to 31 gauge needle (most insulin syringes come with 30 gauge). Pinch a fold of skin, insert at a 45-degree angle, inject slowly. Hold for 5 seconds before withdrawing.

    6. 6
      Inject at a consistent time each day

      Morning is commonly chosen for immune peptides, though no HNP-1-specific timing data exists.

    7. 7
      Step 7

      Start at the beginner dose (50 mcg, 3 times per week) for the first 1 to 2 weeks. Only increase to daily 100 mcg if no excessive injection site inflammation develops.

    8. 8
      Step 8

      Store reconstituted vials upright in the refrigerator at 2 to 8 degrees C. Use within 14 days. Do not freeze reconstituted solution.

    9. 9
      Cycle 8 weeks on, 4 weeks off

      Get bloodwork at baseline, week 4, and week 8 (CBC with differential, CRP, ESR, liver panel).

    Mixing your own vial? Use the Defensin (HNP-1) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

    Defensin (HNP-1) Stacking Protocols

    Works With

    Avoid

    Immunosuppressants (cyclosporine, tacrolimus, mycophenolate)

    HNP-1 activates macrophages and promotes pro-inflammatory cytokines via NF-κB, directly opposing immunosuppressive therapy. In transplant recipients, risks graft rejection.

    Do not combine
    Anticoagulants (heparin, warfarin)

    HNP-1 neutralizes heparin's anticoagulant activity through direct binding. May unpredictably alter anticoagulation parameters.

    Do not combine
    Checkpoint inhibitors (nivolumab, pembrolizumab)

    Combined immune activation effects unstudied. Theoretical risk of excessive immune activation or cytokine storm from dual checkpoint + innate immune stimulation.

    Estimated Cost

    Defensin (HNP-1) Side Effects

    The most serious concern with exogenous HNP-1 is host cell cytotoxicity. At high concentrations, alpha-defensins damage mammalian epithelial and endothelial cell membranes through the same pore-forming mechanism they use on microbes. This is concentration-dependent, not idiosyncratic. Higher doses mean more membrane disruption, and there is no established safe ceiling in humans.

    A mouse study (PMC9355784) found that high-dose exogenous HNP-1 at 10 mg/kg i.p. disrupted liver interendothelial junctions through the NLRP3 inflammasome/caspase-1 pathway. Animals in that study had worsened sepsis outcomes. The dose was 175 to 3,500 times higher than research tiers listed here, but the mechanism is concerning enough that liver function monitoring (ALT, AST) is recommended even at conservative doses.

    Pro-inflammatory cytokine elevation is expected, not a side effect to be dismissed. HNP-1 activates NF-kB, driving TNF-alpha, IL-1beta, and IL-6 release. For someone with underlying autoimmune disease, this could trigger a flare. For anyone on immunosuppressive therapy, it directly opposes the mechanism of drugs like tacrolimus and cyclosporine.

    Injection site reactions are predicted based on the peptide's cationic charge. Redness, swelling, and pain at the injection site reflect local tissue interaction with a positively charged peptide. If injection site inflammation becomes excessive, that signals local cytotoxicity, not an allergic reaction. Reducing dose or frequency is the appropriate response.

    The HIV paradox is not theoretical. HNP-1 kills cell-free HIV in laboratory assays [1]. But a 2015 study in epithelial cell models [2] showed that HNP-1 disrupts epithelial tight junctions, increasing HIV traversal of mucosal barriers. Anyone who is HIV-positive or at high risk of HIV exposure should consider this an absolute contraindication.

    Raised endogenous defensin levels have been associated with atherosclerosis and endothelial dysfunction in observational studies. Extended exogenous use could theoretically worsen cardiovascular risk, particularly in someone with existing vascular disease.

    No formal human adverse event profiles exist. HNP-1 has never entered a Phase I trial. The total number of humans who have received exogenous HNP-1 as a therapeutic agent is effectively zero.

    When to stop: fever above 38 degrees C, any sign of worsening infection, autoimmune flare symptoms (joint pain, unexplained rash, disproportionate fatigue), liver enzymes rising above 2x the upper limit of normal, or any identified HIV exposure risk. Do not attempt to push through these signals.

    Pregnancy and breastfeeding: no reproductive safety data of any kind. This is a hard contraindication.

    Common Issues & Solutions

    Excessive injection site redness/swelling (local cytotoxicity): reduce dose or frequency: this is concentration-dependent host cell membrane interaction, not allergy; cytotoxicity is the primary theoretical risk of exogenous HNP-1.

    Worsening infection symptoms after starting: STOP immediately: high-dose HNP-1 (PMC9355784) disrupts liver interendothelial junctions via NLRP3/caspase-1, worsening sepsis outcomes; never use during active infection.

    Cloudy/aggregated reconstituted vial: defensins aggregate at air-water interfaces; reconstitute by gentle swirling only (no shaking); discard if aggregation persists: injecting aggregated product risks local cytotoxic reaction.

    HIV exposure concern identified: CONTRAINDICATED: HNP-1 paradoxically increases HIV traversal of mucosal epithelial barriers [2] by disrupting tight junctions; this is an absolute contraindication for HIV+ individuals and high-risk settings.

    No measurable immune benefit after 4 weeks: expected finding: no validated human biomarker response exists; all outcome monitoring is exploratory; discontinue if monitoring shows concerning inflammatory or hepatic trends.

    Ask AI about this page

    Ask AI for a second opinion on Defensin (HNP-1) dosing and side effects

    Contraindications

    • Active autoimmune disease: HNP-1 stimulates pro-inflammatory cytokines and immune cell recruitment
    • Acute respiratory distress syndrome (ARDS) or severe pulmonary inflammation
    • Active atherosclerosis or cardiovascular disease: HNP-1 linked to endothelial dysfunction
    • Organ transplant recipients on immunosuppressants: immune activation risks graft rejection
    • Pregnancy or breastfeeding: no reproductive safety data
    • Sepsis or systemic inflammatory response syndrome (SIRS)

    Drug Interactions

    • Immunosuppressants (cyclosporine, tacrolimus, mycophenolate): HNP-1 immune-activating effects may counteract immunosuppressive therapy
    • Corticosteroids: may reduce endogenous defensin release; exogenous HNP-1 effects may be blunted
    • Anticoagulants (heparin, warfarin): HNP-1 can neutralize heparin's anticoagulant activity
    • Other antimicrobial peptides (LL-37, Thymosin Alpha 1): additive or greater immune stimulation
    • Checkpoint inhibitors (nivolumab, pembrolizumab): combined immune activation effects unstudied
    • NSAIDs: may partially counteract HNP-1-induced pro-inflammatory signaling
    • HNP-1 activates macrophages and promotes pro-inflammatory cytokines via NF-κB, directly opposing immunosuppressive therapy. In transplant recipients, risks graft rejection.
    • HNP-1 neutralizes heparin's anticoagulant activity through direct binding. May unpredictably alter anticoagulation parameters.

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    CBC with differentialBaseline, week 4, week 8WBC 4.5–11.0 K/µL; neutrophils 1.8–7.7 K/µL; no significant shift from baseline expected at research doses
    C-Reactive Protein (CRP)Baseline, week 2, week 4, week 8<3 mg/L baseline target; values >10 mg/L warrant dose reduction or discontinuation
    Erythrocyte Sedimentation Rate (ESR)Baseline, week 4, week 8<20 mm/hr (age-adjusted); rising trend warrants reassessment
    Liver function panel (ALT, AST, ALP)Baseline, week 4ALT <56 U/L, AST <40 U/L; any elevation >2× ULN warrants discontinuation
    CBC with differential

    Track neutrophil/monocyte/lymphocyte changes reflecting HNP-1 immunomodulation; detect unexpected cytopenias

    C-Reactive Protein (CRP)

    HNP-1 stimulates pro-inflammatory cytokines (TNF-α, IL-1β via NF-κB); CRP monitors for excessive systemic inflammation

    Erythrocyte Sedimentation Rate (ESR)

    Secondary inflammatory marker; elevated in autoimmune and vasculitic conditions that HNP-1 could exacerbate

    Liver function panel (ALT, AST, ALP)

    PMC9355784 finding: high-dose HNP-1 disrupts liver interendothelial junctions via NLRP3 inflammasome/caspase-1 pathway; hepatic monitoring warranted even at lower research doses

    Defensin (HNP-1) Before and After

    Week 1

    Treatment initiation at low dose. HNP-1 begins circulating and interacting with immune cells. Assess injection site tolerance and monitor for excessive local inflammation. Baseline bloodwork (CBC with differential, CRP, ESR) recommended.

    Weeks 2-3

    Early immunomodulatory effects may begin. Neutrophil and monocyte activity may show subtle enhancement. Dendritic cell recruitment to peripheral tissues is theoretically increased.

    Weeks 4-6

    Cumulative immune priming effects expected. In animal models, sustained defensin exposure produces measurable increases in macrophage phagocytic activity and dendritic cell maturation markers.

    Weeks 6-8

    Peak treatment window. Adaptive immune bridging effects (T-cell recruitment, enhanced antigen presentation) should be most apparent. Full bloodwork recommended.

    What to Expect

    Week 1-2, Tolerance assessment: HNP-1 begins circulating after subcutaneous injection, with an estimated half-life of 3 to 4 hours. The cationic peptide interacts with local tissue at the injection site. Dendritic cell and monocyte chemoattraction through CCR6 binding theoretically starts during this window. Multiple injections per week are needed because the short half-life limits sustained immunomodulatory signaling. Expect injection site redness and mild swelling from the cationic charge interacting with local tissue. Mild flushing is possible from initial cytokine release. No human self-experimentation data exists for this compound; all expectations are extrapolated from animal models and peptide pharmacokinetic class data. Get baseline CBC with differential, CRP, and ESR before the first injection.

    Weeks 2-4, Early immunomodulatory effects (theoretical): Macrophage phagocytic activity may start to increase. Dendritic cell recruitment via CCR6 binding should be ongoing. NK cell activation is theoretically engaged at this point. All of these projections come from in vitro and rodent data only; no human validation exists. Zero community experience is available for comparison. Watch for pro-inflammatory cytokine effects: TNF-alpha and IL-1beta elevation could produce joint pain, rash, or fatigue in susceptible individuals.

    Weeks 4-8, Cumulative immune priming (animal model projection): Rodent studies show sustained defensin exposure produces measurable increases in macrophage phagocytic activity and dendritic cell maturation markers. The adaptive immunity effects (T-cell recruitment, improved antigen presentation) should be most apparent now. CRP and ESR monitoring is important during this phase; cumulative inflammatory load is a real concern. Observational data links raised HNP-1 to endothelial dysfunction, so extended use carries theoretical cardiovascular risk. Full bloodwork at week 4 and week 8, including liver function panel given the PMC9355784 finding on hepatic junction disruption at high doses.

    Detailed Timeline: Science vs Community

    Week 1-2
    Science

    HNP-1 circulates with estimated half-life of 3-4 hours. Electrostatic interaction with local tissue; initial DC/monocyte chemoattraction theoretically begins. Multiple injections per week required for sustained immunomodulatory signaling.

    Community

    No human self-experimentation data: extrapolated from animal models and peptide PK class data only.

    Weeks 2-4
    Science

    Macrophage phagocytic activity enhancement; dendritic cell recruitment via CCR6 binding; NK cell activation. All projections from in vitro and rodent data only: no human validation.

    Community

    No reports: zero community experience available.

    Weeks 4-8
    Science

    In rodent models, sustained defensin exposure produces measurable macrophage phagocytic upregulation and DC maturation marker increases. Adaptive immunity bridging (T-cell recruitment, enhanced antigen presentation) theoretically most apparent at this stage.

    Community

    No reports available.

    Pharmacokinetics

    Half-Life
    3.5h
    Bioavailability
    SC: estimated 60-80% based on peptide size (3,442 Da) and cationic charge
    Tmax
    Estimated 1-2 hours SC based on peptide size and subcutaneous absorption kinetics
    Data Confidence
    low

    Source: No formal PK studies of exogenous HNP-1 in humans. Estimated 3-4 hours based on cationic peptide clearance kinetics for peptides in the 3-4 kDa range.

    Pharmacokinetics: Active Dose Over Time

    t½ = ~3-4 hours (estimated, based on peptide clearance kinetics)

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    30
    Sequence
    ACYCRIPACIAGERRYGTCIYQGRLWAFCC
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

    Who Should Consider Defensin (HNP-1)

    • Researchers studying innate immune defense mechanisms and antimicrobial peptides
    • Scientists investigating host defense peptide-based approaches to antibiotic resistance
    • Researchers exploring defensin-based antitumor peptide strategies
    • Immunologists studying dendritic cell maturation and adaptive immunity bridging
    • Individuals with recurrent infections seeking immune support under medical supervision

    Related Peptides

    What Changed for Defensin (HNP-1)

    1. Evidence

      Corrected Oct 12, 2026: the HNP-1 HIV warning now cites one in vitro study in epithelial cells, after dropping an unrelated paper, per PubMed (PMID 26379091).

      Before: Demirkhanyan et al. (PMID 22647697, 2012) and a 2015 study (PMID 26379091) showed HNP-1 disrupts epithelial tight junctions, increasing HIV traversal After: A 2015 study in epithelial cell models (PMID 26379091) showed HNP-1 disrupts epithelial tight junctions, increasing HIV traversal

      What this does not mean: The warning is unchanged: anyone HIV-positive or at high risk of HIV exposure should treat HNP-1 as contraindicated.

      Source: Viral Immunol 2015, Human Alpha-Defensin HNP1 Increases HIV Traversal of the Epithelial Barrier (Valere et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

    Peptide Schedule Research TeamReviewed Apr 8, 202613 Citations

    References

    1. [1]Human defensins inhibit HIV replication in vitro (Chang et al., 2005) (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Human Alpha-Defensin HNP1 Increases HIV Traversal of the Epithelial Barrier: A Potential Role in STI-Mediated Enhancement of HIV Transmission (Viral Immunol 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
    3. [3]Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 (Yang et al., 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
    4. [4]Defensins: antimicrobial peptides of innate immunity (Ganz, 2003) (opens in a new tab)PubMed (opens in a new tab)Review

    Related Tools

    Storage & Stability

    Before Reconstitution
    Store at -20°C for long-term stability. Stable at 2-8°C for up to 4 weeks.
    After Reconstitution
    Refrigerate at 2-8°C, use within 14 days. Do not freeze reconstituted solution.
    Temperature
    2-8°C (36-46°F) for active use; -20°C for long-term storage

    Frequently Asked Questions

    Both, depending on context. HNP-1 has direct anti-HIV activity in cell-free assays by disrupting the viral envelope and interfering with gp120-mediated fusion. However, a 2015 study (PMID 26379091) found HNP-1 increases HIV traversal of mucosal epithelial barriers by disrupting tight junctions; effectively helping the virus cross into systemic circulation. This makes HNP-1 contraindicated in active HIV infection or high-risk exposure settings.

    Yes at high doses. A mouse study (PMC9355784) found high-dose exogenous HNP-1 (10 mg/kg i.p.) disrupted liver interendothelial junctions via the NLRP3 inflammasome/caspase-1 pathway, worsening sepsis outcomes. Anyone with suspected infection or sepsis risk should not use this compound.

    Manufacturing challenge is the primary barrier. HNP-1 requires three intramolecular disulfide bonds formed in a specific pattern; recombinant production is difficult and expensive, and native purification from neutrophil granules is impractical at scale. A 2025 review (PMC11858525) covers current production strategies.

    No, this is an explicit contraindication. HNP-1 activates macrophages, promotes dendritic cell maturation, and elevates TNF-alpha/IL-1beta through NF-kB. These effects directly oppose immunosuppressive therapy (tacrolimus, cyclosporine, mycophenolate). In transplant recipients, this could trigger graft rejection.

    Alpha-defensins (HNP-1, HNP-2, HNP-3) are stored preformed in neutrophil azurophilic granules and released by degranulation; the "rapid response" innate immune effectors. Beta-defensins (hBD-1, hBD-2, hBD-3) are inducibly expressed by epithelial cells. They have different disulfide bond patterns and distinct pharmacological properties. LL-37 is actually a cathelicidin, not a true defensin.